CTAS — Cintas Corporation

As of 2026-09-23 the tape is constructive but not euphoric. The stock is up 17.77% over three months yet down 2.45% over the past month and 0.08% over the past week, and the RSI of 47.2 is dead-center - the market has cooled off after a strong run and is waiting for proof rather than paying up. The analyst picture matches: the FMP ratings breakdown shows 12 buys, 16 holds and 2 sells (consensus rating 'Hold'), with a $231.25 average price target (high $250, low $214) that implies ~16% upside but rests on only four recent target-setting analysts. Sentiment is also capped by the unresolved FTC antitrust review of the pending UniFirst acquisition, which makes the biggest structural story in the stock a binary the market cannot yet price.

This is a stable-to-modestly-accelerating compounder, not an inflecting one. Revenue YoY has been remarkably consistent for three years: +7.8% (Q2 FY25), +8.4%, +8.0%, +8.7%, +9.3%, +8.9%, +8.9%, and then +10.9% in Q1 FY27 (period ended 2026-08-31) - so the latest quarter is a genuine step up, though management frames organic growth adjusted for workdays and FX at 8.9%, i.e. the headline beat is partly calendar/FX, not a demand breakout. Margins are the real story and they are structural, not a blip: operating margin has climbed from 21.0% in Q2 FY24 (Nov 2023) to 21.6%, 22.2%, 22.4%, 23.1%, 23.4%, 22.4%, 22.7%, 23.4%, 23.2%, 23.2% and now 23.6% in Q1 FY27, with Q1 gross margin up 120bp YoY to 51.5%. Earnings follow: diluted EPS has gone $0.90, $0.96, $1.00, $1.10, $1.09, $1.13, $1.09, $1.20, $1.21, $1.24, $1.26, $1.36. Q1 FY27 net income rose 12.3% YoY to $551.7M on 10.9% revenue growth, operating income rose 15.2%, and operating cash flow rose 38.1% to $572.3M - i.e. profit is growing faster than sales, which is what operating leverage looks like. One data caution: the valuation feed's TTM gross margin of 37.6% contradicts the ~51% implied by the quarterly income statements ($1.48B gross profit on $2.905B revenue in Q4 FY26); I trust the quarterly filings and would ignore the 37.6% figure.

Fairly valued versus its own history, expensive in absolute terms. As of 2026-09-23, at $198.80 the stock trades at 38.75x trailing EPS ($5.15) versus a 5-year average P/E of 39.71x - a slight discount to its own norm - and 36.1x the FY27 consensus EPS of $5.505. P/S of 6.88 is a modest premium to the 5-year average of 6.57, EV/EBITDA is ~27.5x, and the PEG ratio of 3.16 is rich on any normal growth-adjusted scale. In other words, the market is not paying an unusual multiple for Cintas by the standards of the last five years, but it is paying a very high multiple for any business, and the 2.6% trailing FCF yield (~$2.03B TTM FCF on a $79.6B market cap) gives you little valuation cushion. A 23.4% ROIC, 38.9% ROE, 0.246 debt/equity and an AAA-like balance sheet justify a premium - just not an expanding one.

At 36x forward earnings against ~13-15% EPS growth, Cintas is priced for continued execution with essentially zero tolerance for a miss - this is a 'prove it every quarter' multiple, not a re-rating candidate. The stock is up 17.77% over three months yet has given back 2.45% over the past month, which tells you the market already banked the Q1 FY27 beat and guidance raise before the 2026-09-23 print. The interesting asymmetry is that the consensus target of $231.25 (~42x FY27 EPS) requires further multiple expansion beyond even the 5-year average of 39.71x; that is a stretch target, not a base case. Upside from here realistically has to come from earnings delivery (mid-teens adjusted EPS growth, continued gross margin expansion) plus resolution of the UniFirst regulatory question - not from the multiple. The GAAP-vs-adjusted gap also matters: Q1 FY27 adjusted EPS of $1.39 excluded $14.4M of UniFirst deal costs, so GAAP $1.36 understates normalized earnings power by about $0.03/share at current run-rate, and that drag recurs while the deal is pending.

As of 2026-09-23, RSI(14) stood at 47.2 - textbook neutral, with no oversold or overbought signal. Price was 0.89% below its 20-day SMA (~$200.6) and 1.65% below its 50-day SMA (~$202.1), but 5.93% above its 200-day SMA (~$187.7). That combination describes a healthy longer-term uptrend currently in a short-term consolidation, not a breakdown: the stock is up 17.77% over three months and 11.60% over six months while flat-to-down over the last week and month. Practically, there is no urgency to chase here - the stock is mid-range with the 50-day acting as near-term resistance around $202 and the 200-day around $188 as the structural support line. A pullback into the high-$180s/low-$190s would line up with both the long-term trend and a much better risk/reward than buying into the middle of the range. Note the price snapshot coincides with the Q1 FY27 filing date of 2026-09-23, so none of these technical readings yet reflect the market's reaction to the print.

• Small-business labor demand: Cintas's route-based rental volumes scale with customer headcount and blue-collar shift deployment, making it a live proxy for service-sector hiring. The 8.9% organic growth (adjusted for workdays/FX) in Q1 FY27 says the small-business labor market is still holding up, but volumes would react to a hiring contraction faster than pricing would.
• FTC antitrust review of the pending UniFirst acquisition: the single largest regulatory variable the company faces, with three plausible outcomes - clearance, clearance with divestiture conditions, or a block - each producing a very different 2027-2028 earnings profile.
• Wage and input-cost inflation: Cintas has successfully offset it with pricing discipline and route-density efficiency, which is why gross margin expanded 120bp YoY to 51.5% in Q1 FY27. The risk is pricing power normalizing while route wage costs stay sticky.
• Interest rates and discount rates: with long-term debt/equity of just 0.043 and total debt/equity of 0.246, Cintas is barely rate-sensitive on its own balance sheet; the sensitivity is in the multiple, where a 36-39x forward P/E is a long-duration asset that de-rates when long rates rise.
• Quality/defensive sector rotation: recurring-contract revenue and a 0.94% dividend yield keep Cintas bid in risk-off or soft-landing tapes, but the stock can lag in aggressive risk-on rotations into cheaper, higher-beta cyclicals.

• FTC decision or milestone updates on the UniFirst acquisition - the clearest binary in the story. Clearance with manageable conditions would consolidate the North American uniform-rental market and could add meaningful revenue scale; a block or onerous divestiture requirements would strip out the synergy story while leaving the deal costs behind.
• Fiscal Q2 2027 results in late December 2026 - the first clean read on whether Q1 FY27's 10.9% revenue growth and 120bp gross-margin expansion are durable, plus an update on UniFirst transaction costs (the $14.4M charge in Q1 FY27 cost roughly $0.03 of GAAP EPS).
• Continued free-cash-flow compounding: Q1 FY27 FCF of $464.8M was up 48.7% YoY and TTM FCF is ~$2.03B. Sustained conversion supports dividend increases (currently 0.94% yield) and buybacks, which is what keeps the premium multiple defensible.
• Further guidance raises - management just lifted the FY27 revenue midpoint to ~$12.21B and adjusted EPS expectations; another raise would be the trigger that makes the ~$231 consensus target credible rather than aspirational.

• Valuation risk: 36x forward EPS, ~27.5x EV/EBITDA and a 2.6% FCF yield leave no cushion. A single quarter of sub-9% organic growth or flat margins could compress the multiple faster than earnings grow, and the multiple is the largest single contributor to total return at this price.
• UniFirst deal risk: an FTC block, mandated divestitures, or a messy integration would each be value-destructive relative to the current narrative, and legal/transaction costs ($14.4M in Q1 FY27 alone) are a recurring drag while the review is open.
• Labor-market sensitivity: because route volumes track customer headcount, a deterioration in small-business employment hits rental revenue directly and would show up in organic growth before it shows up in the broader economy.
• Pricing-power fade: the margin story (op margin 21.0% to 23.6% over eleven quarters) depends on Cintas continuing to push price ahead of wage inflation; if customers resist renewals, the operating-leverage narrative unwinds quickly.
• Concentrated sell-side conviction: only four analysts contributed to the recent price-target average, and the broader rating mix (12 buys, 16 holds, 2 sells) is a 'Hold' - meaning the stock is not under-owned but also not a high-conviction consensus long.

Cintas is a genuinely high-quality compounder - 23.4% ROIC, 38.9% ROE, debt/equity of only 0.246, eleven consecutive quarters of operating-margin expansion (21.0% to 23.6%), a negative accruals ratio of -0.21% (cash earnings ahead of reported profit), and free cash flow up 48.7% YoY - and as of 2026-09-23 it trades at 36.1x forward FY27 EPS, a slight discount to its own 5-year average of 39.71x. That is a reasonable price for the quality, but it is not cheap, and the 42x-forward-EPS implied by the $231.25 consensus target is not a base case. The honest read: this is a solid long-term holding you can own at $198.80 with moderate upside from earnings growth alone, not a mispriced asset, and the pending FTC review of UniFirst means the single biggest swing factor in the next 12 months is a regulatory coin-flip rather than anything in the financials.

Method: forward P/E applied to consensus FY27 EPS, cross-checked against a simplified DCF and an EV/EBITDA read. Inputs: FY27 consensus EPS of $5.505 and a target multiple of 37.0x - a ~7% haircut to Cintas's own 5-year average P/E of 39.71x, justified by decelerating revenue growth (~9-11% vs. mid-teens historically) and the unresolved UniFirst regulatory overhang, but still a premium multiple warranted by 23.4% ROIC, ~51% gross margin, near-zero net leverage and 49% YoY FCF growth. That gives $5.505 x 37.0 = ~$204. Cross-checks: a simplified DCF (TTM FCF ~$2.03B, 12% five-year growth, 3% terminal, 7% discount rate) yields ~$194/share, and 27x forward EBITDA of ~$3.2B on ~400M shares yields ~$215/share - so $204 sits at the center of the three approaches and implies ~13% upside from the 2026-09-23 price of $198.80, well short of the $231.25 analyst consensus.